Mohammad Darvishi, Mehdi Mohammadian Amiri, Saeid Heidari-Soureshjani, Catherine M T Sherwin, Hossein Mardani-Nafchi
{"title":"The Association between Statins Intake and Risk of Post Stroke Pneumonia: A Systematic Review and Meta-Analysis.","authors":"Mohammad Darvishi, Mehdi Mohammadian Amiri, Saeid Heidari-Soureshjani, Catherine M T Sherwin, Hossein Mardani-Nafchi","doi":"10.2174/0127724328258172230926070748","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>This research aimed to examine the relationship between the intake of statins and the risk of post-stroke pneumonia in a systematic review and meta-analysis study.</p><p><strong>Methods: </strong>An extensive search of published articles on March 2<sup>1st</sup>, 2023, was done in several databases, like Web of Science (ISI), PubMed, Cochrane Library, Embase, Scopus, and Google Scholar. The Newcastle Ottawa Scale (NOS) checklist was employed to evaluate the quality of observational studies. Statistical tests (Chi-square test and I<sup>2</sup>) and graphical techniques (Forest plot) were used to determine whether heterogeneity existed in the meta-analysis studies. Funnel plots and Begg and Egger's tests were used to assess the publication bias.</p><p><strong>Results: </strong>Seven studies (5 cohort and 2 case-control studies) were retrieved to examine the association between statins and post-stroke pneumonia. The sample size of the studies compiled in the meta- analysis was obtained to be 68,966 participants. Meta-analysis demonstrated that the overall odds of post-stroke pneumonia in the statin group was equal to 0.87 (95% CI: 0.67 - 1.13; p-value 0.458). Subgroup analysis indicated that the odds of post-stroke pneumonia in the statin group was equal to 0.93 (95% CI: 0.73-1.18; p-value = 0.558) in the cohort studies, and equal to 0.92 (95% CI: 0.37-2.26; p-value = 0.857) in the case-control studies. The examination of the association between the intake of statins and post-stroke pneumonia showed no evidence of publication bias (Begg's test, p-value = 0.368; Eggers test, p-value = 0.282).</p><p><strong>Conclusion: </strong>In this study, no relationship has been observed between receiving statins and the risk of post-stroke pneumonia.</p>","PeriodicalId":29871,"journal":{"name":"Current Reviews in Clinical and Experimental Pharmacology","volume":" ","pages":"285-293"},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Reviews in Clinical and Experimental Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0127724328258172230926070748","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: This research aimed to examine the relationship between the intake of statins and the risk of post-stroke pneumonia in a systematic review and meta-analysis study.
Methods: An extensive search of published articles on March 21st, 2023, was done in several databases, like Web of Science (ISI), PubMed, Cochrane Library, Embase, Scopus, and Google Scholar. The Newcastle Ottawa Scale (NOS) checklist was employed to evaluate the quality of observational studies. Statistical tests (Chi-square test and I2) and graphical techniques (Forest plot) were used to determine whether heterogeneity existed in the meta-analysis studies. Funnel plots and Begg and Egger's tests were used to assess the publication bias.
Results: Seven studies (5 cohort and 2 case-control studies) were retrieved to examine the association between statins and post-stroke pneumonia. The sample size of the studies compiled in the meta- analysis was obtained to be 68,966 participants. Meta-analysis demonstrated that the overall odds of post-stroke pneumonia in the statin group was equal to 0.87 (95% CI: 0.67 - 1.13; p-value 0.458). Subgroup analysis indicated that the odds of post-stroke pneumonia in the statin group was equal to 0.93 (95% CI: 0.73-1.18; p-value = 0.558) in the cohort studies, and equal to 0.92 (95% CI: 0.37-2.26; p-value = 0.857) in the case-control studies. The examination of the association between the intake of statins and post-stroke pneumonia showed no evidence of publication bias (Begg's test, p-value = 0.368; Eggers test, p-value = 0.282).
Conclusion: In this study, no relationship has been observed between receiving statins and the risk of post-stroke pneumonia.
目的:本研究旨在通过系统综述和荟萃分析研究来检验他汀类药物的摄入与卒中后肺炎风险之间的关系。方法:在多个数据库中广泛搜索2023年3月21日发表的文章,如Web of Science(ISI)、PubMed、Cochrane Library、Embase、Scopus和Google Scholar。纽卡斯尔-渥太华量表(NOS)用于评估观察性研究的质量。统计检验(卡方检验和I2)和图形技术(森林图)用于确定荟萃分析研究中是否存在异质性。漏斗图和Begg和Egger检验用于评估发表偏倚。结果:检索了7项研究(5项队列研究和2项病例对照研究),以检查他汀类药物与脑卒中后肺炎之间的关系。荟萃分析中汇编的研究样本量为68966名参与者。荟萃分析表明,他汀类药物组发生脑卒中后肺炎的总几率为0.87(95%CI:0.67-1.13;p值0.458)。亚组分析表明,在队列研究中,他汀类化合物组发生脑缺血后肺炎的几率为0.93(95%CI:0.73-1.18;p值=0.558),在病例对照研究中为0.92(95%CI:0.37-2.26;p值0.857)。对他汀类药物摄入与卒中后肺炎之间关系的检查没有显示出发表偏倚的证据(Begg’s检验,p值=0.368;Eggers检验,p值=0.822)。结论:在本研究中,未观察到接受他汀类药物与卒中后肺炎风险之间的关系。